Invitation: PROSTVAC(TM) Wrap up
May 27 2009 - 11:04AM
PR Newswire (US)
KVISTGAARD, Denmark, May 27 /PRNewswire-FirstCall/ -- Following the
presentation of data with PROSTVAC(TM) - a promising, late-stage
vaccine candidate for the treatment of advanced prostate cancer,
Bavarian Nordic will be hosting a Q&A session at the ASCO
Annual Meeting. Time: Sunday, May 31st 2009 from 09 AM EDT to 10 AM
EDT. Location: Rosen Centre Hotel, 9840 International Drive,
Orlando, Florida 32819 At the Q&A session, Bavarian Nordic's
PROSTVAC(TM) team and President & CEO, Anders Hedegaard will
attend. The Q&A session follows the presentation of final Phase
2 data with PROSTVAC(TM) at the 2009 ASCO Annual Meeting. The
presentation will take place on May 30, 2009 at 5:00 PM EDT and
will be held by Philip Kantoff, MD, Professor of Medicine, Harvard
Medical School, and the Dana-Farber Cancer Institute who is also
principal investigator in the study. Looking forward to seeing you
there! About PROSTVAC(TM) PROSTVAC(TM) is a therapeutic vaccine
moving into late stage clinical development. PROSTVAC(TM) has the
potential to extend survival with improved quality of life in
patients with advanced prostate cancer. About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company
developing and producing novel vaccines for the treatment and
prevention of life-threatening diseases with a large unmet medical
need. The company's business strategy is focused in three areas:
biodefence, cancer and infectious diseases. Bavarian Nordic is
listed on NASDAQ OMX Copenhagen under the symbol BAVA. For more
information please visit http://www.bavarian-nordic.com/
DATASOURCE: Bavarian Nordic A/S CONTACT: Anders Hedegaard,
+45-2320-3064
Copyright